Download PDF
Horm Metab Res 2019; 51(10): 649-654
DOI: 10.1055/a-0998-4079
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly

Hamide Piskinpasa
1   Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Yildiz Okuturlar
2   Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Sema Ciftci Dogansen
1   Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Yasemin Sefika Akdeniz
1   Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Ayse Esen
1   Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Sogol Sadri
2   Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Osman Pirhan
3   Department of Cardiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Aysegul Akdogan Gemici
4   Department of Radiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Sibel Ocak Serin
5   Department of Internal Medicine, Umraniye Training and Research Hospital, Istanbul, Turkey
,
Asuman Gedikbası
6   Department of Biochemistry, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
,
Mine Adas
7   Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey
,
Meral Mert
1   Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
› Author Affiliations
Further Information

Publication History

received 08 March 2019

accepted 06 August 2019

Publication Date:
05 September 2019 (online)

Also available at
    Permissions and Reprints

Abstract

The purpose of the study was to compare serum visfatin levels between patients with acromegaly and healthy controls and to evaluate the relationships between visfatin levels and epicardial fat thickness (EFT), carotid intima media thickness (cIMT), and ankle brachial index (ABI). We conducted a cross-sectional case-control study of 54 patients with acromegaly (37 females and 17 males) and 34 healthy controls (22 females and 12 males). Serum visfatin was measured by ELISA. Acromegalic and control participants and those with active or controlled acromegaly were compared with respect to their serum visfatin, clinical and metabolic parameters, EFT, cIMT, and ABI. Linear correlation was used to identify associations between these parameters and visfatin in all participants. Serum visfatin and glycated hemoglobin (HbA1c) were higher in the acromegaly group than in the control group (p<0.001 and p=0.007, respectively). There was no difference in visfatin between the active and controlled acromegaly groups, but HbA1c was higher in the active than the controlled acromegaly group (p<0.04). EFT, cIMT, and ABI were similar between the acromegaly and control groups and between the active and controlled acromegaly groups. Serum visfatin positively correlated with HbA1c, growth hormone (GH), and insulin-like growth factor-1 (IGF-1)/upper limit of normal ratio (r=0.245, p=0.024; r=0.259, p=0.017; and r=0.282, p=0.009, respectively). This study has revealed that a high visfatin level is associated with glycemic dysregulation and higher levels of GH and IGF-1 in acromegalic patients.

Key words

visfatin - acromegaly - diabetes mellitus - epicardial fat thickness - carotid intima media thickness
 

  • References

  • 1 Katznelson L, Laws Jr. ER, Melmed S. et al. Endocrine Society. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
    CrossrefPubMedGoogle Scholar
  • 2 Melmed S, Casanueva FF, Klibanski A. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013; 16: 294-302
    CrossrefPubMedGoogle Scholar
  • 3 Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152-177
    CrossrefPubMedGoogle Scholar
  • 4 Frara S, Maffezzoni F, Mazziotti G. et al. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 2016; 27: 470-483
    CrossrefPubMedGoogle Scholar
  • 5 Dogansen SC, Yalin GY, Tanrikulu S. et al. Impact of glucose metabolism disorders on IGF-1 levels in patients with acromegaly. Horm Metab Res 2018; 50: 408-413
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. Front Horm Res 2018; 49: 20-28
    CrossrefPubMedGoogle Scholar
  • 7 Ritvonen E, Löyttyniemi E, Jaatinen P. et al. Mortality in acromegaly: A 20-year follow-up study. Endocr Relat Cancer 2016; 23: 469-480
    CrossrefPubMedGoogle Scholar
  • 8 Olarescu NC, Bollerslev J. The impact of adipose tissue on IR in acromegaly. Trends Endocrinol Metab 2016; 27: 226-237
    CrossrefPubMedGoogle Scholar
  • 9 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
    CrossrefPubMedGoogle Scholar
  • 10 Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin. Science 2005; 307: 426-430
    CrossrefPubMedGoogle Scholar
  • 11 Uzun G, Ozden S. Visfatin and its effects. Journal of Turkish Clinical Biochemistry 2013; 11: 119-130
    PubMedGoogle Scholar
  • 12 Sucunza N, Barahona MJ, Resmini E. et al. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009; 94: 3889-3896
    CrossrefPubMedGoogle Scholar
  • 13 Olarescu NC, Ueland T, Lekva T. et al. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. J Clin Endocrinol Metab 2012; 97: 1355-1362
    CrossrefPubMedGoogle Scholar
  • 14 Ciresi A, Amato MC, Pizzolanti G. et al. Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations. Growth Horm IGF Res 2015; 25: 240-246
    CrossrefPubMedGoogle Scholar
  • 15 Cansu GB, Yılmaz N, Yanıkoğlu A. et al. Assessment of diastolic dysfunction, arterial stiffness, and carotid intima-media thickness in patients with acromegaly. Endocr Pract 2017; 23: 536-545
    CrossrefPubMedGoogle Scholar
  • 16 Ozkan C, Altinova AE, Cerit ET. et al. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 2015; 18: 621-629
    CrossrefPubMedGoogle Scholar
  • 17 World Health Organization. Physical Status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452
    PubMedGoogle Scholar
  • 18 American Diabetes Association. Standarts of medical care in in diabetes. Classification and diagnosis of diabetes mellitus. Diabetes Care 2016; 39: 13-23
    CrossrefPubMedGoogle Scholar
  • 19 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: IR and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
    CrossrefPubMedGoogle Scholar
  • 20 Iacobellis G, Ribaudo MC, Assael F. et al. Echocardio-graphic epicardial adipose tissue is related to anthropometricand clinical parameters of metabolic syndrome: A new indicatorof cardiovascular risk. J Clin Endocrinol Metab 2003; 88: 5163-5168
    CrossrefPubMedGoogle Scholar
  • 21 Fowkes FG, Murray GD, Butcher I. et al. Ankle brachial index combined with Framingham Risk Score to predict cardio-vascular events and mortality: A meta-analysis. JAMA 2008; 300: 197-208
    CrossrefPubMedGoogle Scholar
  • 22 Giustina A, Chanson P, Bronstein MD. et al. Acromegaly Consensus Group A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148
    CrossrefPubMedGoogle Scholar
  • 23 Goodman HM. Multiple effects of growth hormone on lipolysis. Endocrinology 1968; 83: 300-308
    CrossrefPubMedGoogle Scholar
  • 24 Freda PU, Shen W, Heymsfield SB. et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth fact or I excess due to acromegaly. J Clin Endocrinol Metab 2008; 93: 2334-2343
    CrossrefPubMedGoogle Scholar
  • 25 Ciresi A, Amato MC, Pivonello R. et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013; 98: 51-59
    CrossrefPubMedGoogle Scholar
  • 26 Moschen AR, Kaser A, Enrich B. et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758
    CrossrefPubMedGoogle Scholar
  • 27 Dahl TB, Yndestad A, Skjelland M. et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980
    CrossrefPubMedGoogle Scholar
  • 28 Chen MP, Chung FM, Chang DM. et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
    CrossrefPubMedGoogle Scholar
  • 29 Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M. et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875
    CrossrefPubMedGoogle Scholar
  • 30 Li L, Yang G, Li Q. et al. Changes and relations ofcirculating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-548
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Gunduz FO, Yildirmak ST, Temizel M. et al. Serum visfatin and fetuin-A levels and glycemic control in patients with obese type 2 diabetes mellitus. Diabetes Metab J 2011; 35: 523-538
    CrossrefPubMedGoogle Scholar
  • 32 Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012; 4: 76-81
    CrossrefPubMedGoogle Scholar
  • 33 Olszanecka-Glinianowicz M, Owczarek A, Bożentowicz-Wikarek M. et al. Relationship between circulating visfatin/NAMPT, nutritional status and IR in an elderly population - results from the PolSenior substudy. Metabolism 2014; 63: 1409-1418
    CrossrefPubMedGoogle Scholar
  • 34 Dogru T, Sonmez A, Tasci I. et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29
    CrossrefPubMedGoogle Scholar
  • 35 Turgut S, Topsakal S, Ata MT. et al. Leptin receptor gene polymorphism may affect subclinical atherosclerosis in patients with acromegaly. Avicenna J Med Biotech 2016; 8: 145-150
    PubMedGoogle Scholar
  • 36 Topsakal S, Akin F, Turgut S. et al. Relationship of apelin, procalcitonin, and fetuin-A concentrations with carotid intima-media thickness in acromegaly. Ann Clin Biochem 2015; 52: 456-461
    CrossrefPubMedGoogle Scholar